Navigation Links
Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
Date:10/21/2009

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with an undisclosed client. According to the agreement, Laureate will develop the process to manufacture a unique Fc Fusion Protein and produce this product under cGMP conditions for use in clinical trials. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"This project is a great fit with the experience that we have developed over the past few years working with fusion proteins," said Robert J. Broeze, Ph. D., President & CEO of Laureate Pharma. "We have had great success working with these unique protein products and are delighted to have the opportunity to help advance this product into the clinic."

"We are seeing a strong trend in the biopharmaceutical industry to develop fusion protein products with unique properties," commented Dan Leone, Vice President, Business Development of Laureate Pharma. "Along with monoclonal antibodies, manufacturing fusion proteins has become one of Laureate's core competencies."

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, NJ. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Dan Leone, Vice President, Business Development at 609-919-3300, or info@laureatepharma.com or visit www.laureatepharma.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze | https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=84360

SOURCE Laureate Pharma, Inc.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobel Laureate Dr. Gunter Blobel to Speak at Florida Atlantic University
2. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
3. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. ISTA Pharmaceuticals to Present at 2009 BIOCOM Investor Conference
9. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
10. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
11. Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... BOSTON , April 19, 2017  New research provides ... with advanced Parkinson,s, according to a study released today that ... 69th Annual Meeting in Boston , ... comes to the treatment of Parkinson,s disease, the oral drug ... of life and longevity. But as the disease progresses, the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy ... nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch of ... moisturizer with the power of an anti-aging concentrate. , Anogeissus Leiocarpa ...
(Date:4/28/2017)... NY (PRWEB) , ... April 28, 2017 , ... ... celebrating its 5th anniversary. SearchLight is the premier online modeling resource for fluorescence ... more than 30,000 active users during last 5 years spanning the globe, SearchLight ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... Minneapolis, Minnesota (PRWEB) , ... April 27, 2017 ... ... Smith and her husband Dan Gasby the 2017 Public Leadership in Neurology Award ... Bob Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael ...
(Date:4/27/2017)... ... 27, 2017 , ... Goodcents Deli Fresh Subs announced a franchise expansion agreement ... year. , The first new location will open at the corner of 27th ... and Northern Lights Drive this fall. And the third location is in the process ...
Breaking Medicine News(10 mins):